Skip to main content
Signal8

Roche Holding AG (RHHBF)

Sector: Drug Manufacturers - General

Industry: Drug Manufacturers - General

Roche Holding AG logo

Roche Holding AG

OTC:RHHBFHealthcare
-0.62%$488.47
Mkt Cap$389.2B
Float216.65M
O/S796.77M
Inst Own-
EarningsJan 28 · in 3mo
Div Yield2.54%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 2026488.47488.47488.47488.474
Nov 4, 2026491.50491.50491.50491.5022
Nov 3, 2026490.00490.00490.00490.001
Nov 2, 2026505.00505.00491.13491.1341
Oct 30, 2026500.01502.75500.01501.046
Oct 29, 2026475.00500.00475.00490.0032
Oct 26, 2026474.90474.90474.90474.904
Oct 23, 2026492.81492.81492.81492.815
Oct 21, 2026476.79480.00476.79480.0090
Oct 20, 2026474.00479.43474.00479.433
Oct 15, 2026441.30458.47441.30458.478
Oct 14, 2026460.00460.00460.00460.0070
Oct 13, 2026463.00463.00420.84442.2732
Oct 12, 2026450.00464.38450.00464.386
Oct 9, 2026463.14463.14421.66442.9739
Oct 8, 2026448.76448.76412.89422.85321
Oct 7, 2026440.00444.28435.00435.75358
Oct 6, 2026427.55427.99419.92427.9911
Oct 5, 2026419.92419.92419.92419.9212
Oct 2, 2026419.92419.92419.92419.92147
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
3
HOLD
5
SELL
1
TOTAL9
About

Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors.

Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets.

The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).

Key Metrics
Market Cap$389.20B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 796.77M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - General
ExchangeOTC
CountryCHCH
IPO Date-
Shares Outstanding796.77M
Authorized Shares
Float216.65M
52-Week Range
$351.11$514.08
$488.47(84th percentile)
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
TTM Yield
2.54%
Paid annually
Annual (LTM)
$12.41
Latest
$12.4084
Mar 13, 26
5Y Growth
+4.68%
per year